AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 8172701 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical treatment evaluation method
Number of subjects: 0
Study 31697729 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (5 mg.kg-1 body mass)
Number of subjects: 11
Study 31697729 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 30240030 — intervention group
Group type: EXPERIMENTAL
Intervention: Inference-to-alternates effect observed in a binary context
Number of subjects: 9
Study 30240030 — intervention group
Group type: EXPERIMENTAL
Intervention: Prior experience with similar inferences
Number of subjects: 9
Study 30240030 — intervention group
Group type: EXPERIMENTAL
Intervention: Indicative conditionals
Number of subjects: 9
Study 26966823 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based calisthenic exercises
Number of subjects: 40
Study 26966823 — intervention group
Group type: EXPERIMENTAL
Intervention: Hospital-based calisthenic exercises
Number of subjects: 40
Study 23796803 — intervention group
Group type: EXPERIMENTAL
Intervention: External focus (EF) of attention
Number of subjects: 42
Study 23796803 — intervention group
Group type: COMPARATOR
Intervention: Internal focus (IF) of attention
Number of subjects: 42
Study 22118603 — intervention group
Group type: EXPERIMENTAL
Intervention: Soflens Daily Disposable for Astigmatism (toric lenses)
Number of subjects: 41
Study 22118603 — intervention group
Group type: COMPARATOR
Intervention: Soflens Daily Disposable (spherical lenses)
Number of subjects: 41
Study 19906075 — intervention group
Group type: EXPERIMENTAL
Intervention: Alitretinoin 30 mg once daily for 12-24 weeks
Number of subjects: 117
Study 19906075 — intervention group
Group type: EXPERIMENTAL
Intervention: Alitretinoin 10 mg once daily for 12-24 weeks
Number of subjects: 117
Study 19906075 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 117
Study 18678156 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA) group A with cluster waves of 100 Hz
Number of subjects: 109
Study 18678156 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA) group B with continuous waves of 50 Hz
Number of subjects: 109
Study 18678156 — intervention group
Group type: COMPARATOR
Intervention: Medication group (no EA)
Number of subjects: 109
Study 15368546 — intervention group
Group type: EXPERIMENTAL
Intervention: ALL-DS
Number of subjects: 59
Study 15368546 — intervention group
Group type: COMPARATOR
Intervention: ALL-NDS
Number of subjects: 59
Study 12580681 — intervention group
Group type: EXPERIMENTAL
Intervention: Home intervention with weekly visits from 0 to 6 months and biweekly visits from 6 to 18 months
Number of subjects: 108
Study 12580681 — intervention group
Group type: COMPARATOR
Intervention: Control group received brief monthly tracking visits
Number of subjects: 108
Study 12580681 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (intervention and control)
Number of subjects: 108
Study 10539123 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous ganciclovir (5 mg/kg/day)
Number of subjects: 117
Study 10539123 — intervention group
Group type: COMPARATOR
Intervention: Oral ganciclovir (3000 mg/day)
Number of subjects: 117
Study 8768860 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination recombinant human GH (rhGH; 0.34 mg, sc, twice daily) and rhIGF‐I (5.0 mg, sc, twice daily)
Number of subjects: 142
Study 8768860 — intervention group
Group type: COMPARATOR
Intervention: Placebo injections
Number of subjects: 142
Study 1743712 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon alfa 2a 1.5 million units three times weekly for four weeks
Number of subjects: 154
Study 1743712 — intervention group
Group type: COMPARATOR
Intervention: Podophyllin resin 25% applied to lesions twice weekly for up to six weeks
Number of subjects: 154
Study 7103445 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceforanide (30 mg/kg)
Number of subjects: 26
Study 7103445 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefamandole (30 mg/kg)
Number of subjects: 26
Study 7103445 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceforanide
Number of subjects: 26
Study 7103445 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefamandole
Number of subjects: 26
Study 31315868 — intervention group
Group type: EXPERIMENTAL
Intervention: Telehealth counselling intervention (12 sessions, 20-30 minutes each)
Number of subjects: 80
Study 31315868 — intervention group
Group type: EXPERIMENTAL
Intervention: Text message check-ins and appointment reminders
Number of subjects: 80
Study 31315868 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical outcomes (plasma HIV RNA and CD4+ cell count)
Number of subjects: 80
Study 29857783 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate/formoterol fumarate (Flutiform®; 100/10 µg b.i.d.)
Number of subjects: 512
Study 27163503 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 mg Opicapone (OPC)
Number of subjects: 0
Study 27163503 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg Opicapone (OPC)
Number of subjects: 0
Study 27163503 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg Opicapone (OPC)
Number of subjects: 0
Study 27163503 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard-release 100/25 mg levodopa/carbidopa (LC) or levodopa/benserazide (LB) with Opicapone
Number of subjects: 0
Study 27163503 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLC)
Number of subjects: 0
Study 25434320 — intervention group
Group type: EXPERIMENTAL
Intervention: Drotaverine hydrochloride 80 mg tablet given thrice a day
Number of subjects: 180
Study 25434320 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 180
Study 22866682 — intervention group
Group type: EXPERIMENTAL
Intervention: Preview sentences condition
Number of subjects: 2
Study 22866682 — intervention group
Group type: EXPERIMENTAL
Intervention: Headings condition
Number of subjects: 2
Study 22866682 — intervention group
Group type: EXPERIMENTAL
Intervention: Five headings conditions during TTS presentation
Number of subjects: 2
Study 20377423 — intervention group
Group type: EXPERIMENTAL
Intervention: RBV 2000 mg/day plus EPO 30,000 IU/week
Number of subjects: 149
Study 20377423 — intervention group
Group type: COMPARATOR
Intervention: Weight-based RBV (1000-1200 mg/day)
Number of subjects: 149
Study 18726926 — intervention group
Group type: EXPERIMENTAL
Intervention: Good outcome cases (psychotherapy with good therapeutic outcome)
Number of subjects: 2
Study 18726926 — intervention group
Group type: COMPARATOR
Intervention: Bad outcome cases (psychotherapy with bad therapeutic outcome)
Number of subjects: 2
Study 16154480 — intervention group
Group type: COMPARATOR
Intervention: Valsartan 160 mg OD (V160)
Number of subjects: 774
Study 16154480 — intervention group
Group type: EXPERIMENTAL
Intervention: Valsartan 160 mg OD plus Hydrochlorothiazide 12.5 mg OD (V160 + HCTZ12.5)
Number of subjects: 774
Study 16154480 — intervention group
Group type: EXPERIMENTAL
Intervention: Valsartan 160 mg OD plus Hydrochlorothiazide 25 mg OD (V160 + HCTZ25)
Number of subjects: 774
Study 12235507 — intervention group
Group type: EXPERIMENTAL
Intervention: Robotic assistant (EndoAssist)
Number of subjects: 93
Study 12235507 — intervention group
Group type: COMPARATOR
Intervention: Human assistant
Number of subjects: 93
Study 9915392 — intervention group
Group type: EXPERIMENTAL
Intervention: Rigid fixation
Number of subjects: 125
Study 9915392 — intervention group
Group type: COMPARATOR
Intervention: Wire osteosynthesis
Number of subjects: 125
Study 7578641 — intervention group
Group type: EXPERIMENTAL
Intervention: Cued condition (instructional cues on measures of visual and semantic memory, executive function, and constructional ability)
Number of subjects: 48
Study 7578641 — intervention group
Group type: COMPARATOR
Intervention: Standard condition (performed the same neuropsychological measures without cues)
Number of subjects: 48
Study 2265733 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous subcutaneous insulin infusion pump therapy (CSII)
Number of subjects: 30
Study 2265733 — intervention group
Group type: COMPARATOR
Intervention: Conventional injection therapy (CT)
Number of subjects: 30
Study 6778239 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketotifen
Number of subjects: 36
Study 6778239 — intervention group
Group type: COMPARATOR
Intervention: Disodium cromoglycate (DSCG)
Number of subjects: 36
Study 30320641 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone (8 mg) in group D
Number of subjects: 180
Study 30320641 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine (1.5 mg/kg) in group L
Number of subjects: 180
Study 30320641 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine (1.5 mg/kg) with Dexamethasone (8 mg) in group DL
Number of subjects: 180
Study 30320641 — intervention group
Group type: COMPARATOR
Intervention: Placebo (normal saline) in group NS
Number of subjects: 180
Study 28644768 — intervention group
Group type: EXPERIMENTAL
Intervention: 100% feedback group (feedback on 3 movement reversals after each trial)
Number of subjects: 42
Study 28644768 — intervention group
Group type: EXPERIMENTAL
Intervention: 14% feedback group (14% frequency according to a fading schedule)
Number of subjects: 42
Study 27159624 — intervention group
Group type: EXPERIMENTAL
Intervention: Group DM (0.1 mg/kg dezocine + 0.05 mg/kg midazolam)
Number of subjects: 160
Study 27159624 — intervention group
Group type: COMPARATOR
Intervention: All groups (including control)
Number of subjects: 160
Study 27159624 — intervention group
Group type: COMPARATOR
Intervention: All groups
Number of subjects: 160
Study 27159624 — intervention group
Group type: EXPERIMENTAL
Intervention: Groups D and DM (0.1 mg/kg dezocine)
Number of subjects: 160
Study 27159624 — intervention group
Group type: EXPERIMENTAL
Intervention: Groups M and DM (0.05 mg/kg midazolam)
Number of subjects: 160
Study 27159624 — intervention group
Group type: EXPERIMENTAL
Intervention: Group D (0.1 mg/kg dezocine)
Number of subjects: 160
Study 27159624 — intervention group
Group type: EXPERIMENTAL
Intervention: Group M (0.05 mg/kg midazolam)
Number of subjects: 160
Study 24702172 — intervention group
Group type: EXPERIMENTAL
Intervention: One-set resistance exercise trial (14-min)
Number of subjects: 8
Study 24702172 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-set resistance exercise trial (28-min)
Number of subjects: 8
Study 24702172 — intervention group
Group type: EXPERIMENTAL
Intervention: Three-set resistance exercise trial (42-min)
Number of subjects: 8
Study 24702172 — intervention group
Group type: COMPARATOR
Intervention: Resting control trial
Number of subjects: 8
Study 22520843 — intervention group
Group type: EXPERIMENTAL
Intervention: BCAA supplementation
Number of subjects: 27
Study 22520843 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 27
Study 20462437 — intervention group
Group type: EXPERIMENTAL
Intervention: Floseal
Number of subjects: 30
Study 20462437 — intervention group
Group type: COMPARATOR
Intervention: ISC
Number of subjects: 30
Study 20462437 — intervention group
Group type: EXPERIMENTAL
Intervention: Floseal and ISC
Number of subjects: 30
Study 18570058 — intervention group
Group type: EXPERIMENTAL
Intervention: 17-beta estradiol (E(2))
Number of subjects: 27
Study 18570058 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study 15804727 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.45 mg of conjugated equine estrogens, 50 microg weekly transdermal estradiol (combined with cyclic oral, micronized progesterone, 200 mg for 12 days each month)
Number of subjects: 720
Study 15804727 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 720
Study 12600867 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple micronutrient (MM) supplementation, 6 days/week, containing 60 mg Fe and additional micronutrients (1-1.5 times the recommended dietary allowances)
Number of subjects: 873
Study 12600867 — intervention group
Group type: COMPARATOR
Intervention: Iron-only supplementation, 6 days/week, containing 60 mg Fe
Number of subjects: 873
Study 10978257 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin therapy (20 mg per day for 4 months)
Number of subjects: 64
Study 10978257 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin therapy
Number of subjects: 64
Study 8986917 — intervention group
Group type: EXPERIMENTAL
Intervention: Valsartan 80 mg once a day
Number of subjects: 348
Study 8986917 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril 20 mg once a day
Number of subjects: 348
Study 8986917 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 348
Study 1335643 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccine-induced antibodies after booster dose
Number of subjects: 0
Study 1335643 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccine-induced antibodies after primary doses
Number of subjects: 0
Study 1335643 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccine-induced antibodies considering minimal individual titre
Number of subjects: 0
Study 3992397 — intervention group
Group type: EXPERIMENTAL
Intervention: Premature formula for a further 8 weeks
Number of subjects: 10
Study 3992397 — intervention group
Group type: COMPARATOR
Intervention: Standard infant formula
Number of subjects: 10
Study 30608444 — intervention group
Group type: EXPERIMENTAL
Intervention: OSTAP block with 40 mL of 0.375% bupivacaine
Number of subjects: 66
Study 30608444 — intervention group
Group type: COMPARATOR
Intervention: Sham group with 40 mL of 0.9% saline
Number of subjects: 66
Study 30608444 — intervention group
Group type: EXPERIMENTAL
Intervention: OSTAP block
Number of subjects: 66
Study 30608444 — intervention group
Group type: COMPARATOR
Intervention: Sham group
Number of subjects: 66
Study 28371204 — intervention group
Group type: EXPERIMENTAL
Intervention: Tripeptide/hexapeptide system
Number of subjects: 15
Study 28371204 — intervention group
Group type: COMPARATOR
Intervention: Bland dimethicone-based ointment and petrolatum-based cream
Number of subjects: 15
Study 26643786 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical methyl aminolevulinate (MAL) and daylight
Number of subjects: 60
Study 26643786 — intervention group
Group type: COMPARATOR
Intervention: Placebo and daylight
Number of subjects: 60
Study 23934539 — intervention group
Group type: EXPERIMENTAL
Intervention: SPTB (spontaneous preterm birth)
Number of subjects: 606
Study 23934539 — intervention group
Group type: EXPERIMENTAL
Intervention: IPTB (medically indicated preterm birth)
Number of subjects: 606
Study 23934539 — intervention group
Group type: COMPARATOR
Intervention: Composite neonatal morbidity
Number of subjects: 606
Study 23934539 — intervention group
Group type: COMPARATOR
Intervention: NICU admission
Number of subjects: 606
Study 23934539 — intervention group
Group type: COMPARATOR
Intervention: Perinatal death
Number of subjects: 606
Study 21730016 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiagabine (4 mg, 8 mg, 12 mg)
Number of subjects: 12
Study 21730016 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 21730016 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiagabine
Number of subjects: 12
Study 20560291 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled iloprost (5 mcg every 2-3 hours while awake)
Number of subjects: 22
Study 17200170 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise training + weight loss (AEX + WL)
Number of subjects: 46
Study 17200170 — intervention group
Group type: COMPARATOR
Intervention: Aerobic exercise training (AEX)
Number of subjects: 46
Study 15850603 — intervention group
Group type: EXPERIMENTAL
Intervention: Estrogen (conjugated equine estrogen [CEE] 0.625 mg)
Number of subjects: 94
Study 15850603 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen 20 mg
Number of subjects: 94
Study 15850603 — intervention group
Group type: EXPERIMENTAL
Intervention: Raloxifene 60 mg
Number of subjects: 94
Study 15850603 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 94
Study 11975107 — intervention group
Group type: EXPERIMENTAL
Intervention: Micropuncture technique
Number of subjects: 48
Study 11975107 — intervention group
Group type: COMPARATOR
Intervention: Large-bore needle approach
Number of subjects: 48
Study 10096309 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol (blood alcohol concentration mean = .08 mg%)
Number of subjects: 161
Study 10096309 — intervention group
Group type: EXPERIMENTAL
Intervention: Expectation of alcohol disinhibition
Number of subjects: 161
Study 10096309 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 161
Study 10096309 — intervention group
Group type: COMPARATOR
Intervention: Water
Number of subjects: 161
Study 7635769 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment duration < 55 days
Number of subjects: 209
Study 7635769 — intervention group
Group type: COMPARATOR
Intervention: Treatment duration >= 55 days
Number of subjects: 209
Study 7635769 — intervention group
Group type: EXPERIMENTAL
Intervention: Stage IB/IIA treatment duration < 55 days
Number of subjects: 209
Study 7635769 — intervention group
Group type: COMPARATOR
Intervention: Stage IB/IIA treatment duration >= 55 days
Number of subjects: 209
Study 7635769 — intervention group
Group type: EXPERIMENTAL
Intervention: Stage III treatment duration < 55 days
Number of subjects: 209
Study 7635769 — intervention group
Group type: COMPARATOR
Intervention: Stage III treatment duration >= 55 days
Number of subjects: 209
Study 7635769 — intervention group
Group type: EXPERIMENTAL
Intervention: Stage IIB treatment duration < 55 days
Number of subjects: 209
Study 7635769 — intervention group
Group type: COMPARATOR
Intervention: Stage IIB treatment duration >= 55 days
Number of subjects: 209
Study 2144391 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular vaccination (20 micrograms)
Number of subjects: 69
Study 2144391 — intervention group
Group type: COMPARATOR
Intervention: Intradermal vaccination (2 micrograms)
Number of subjects: 69
Study 625669 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenoxybenzamine prophylaxis
Number of subjects: 43
Study 625669 — intervention group
Group type: COMPARATOR
Intervention: Control group (no phenoxybenzamine)
Number of subjects: 43
Study 625669 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenoxybenzamine treatment after urinary retention
Number of subjects: 43
Study 30973482 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity agility exergaming (EXE)
Number of subjects: 55
Study 30973482 — intervention group
Group type: EXPERIMENTAL
Intervention: Stationary cycling (CYC)
Number of subjects: 55
Study 30973482 — intervention group
Group type: COMPARATOR
Intervention: Waitlisted controls (CON)
Number of subjects: 55
Study 28019652 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduction in WHO risk drinking levels during treatment
Number of subjects: 1383
Study 28019652 — intervention group
Group type: EXPERIMENTAL
Intervention: Greater reduction in WHO risk drinking levels
Number of subjects: 1383
Study 25678325 — intervention group
Group type: EXPERIMENTAL
Intervention: INCENT (individually targeted Internet‐based intervention with monetary incentives)
Number of subjects: 1790
Study 25678325 — intervention group
Group type: COMPARATOR
Intervention: LMW (Livin' My Weigh, less‐intensive intervention)
Number of subjects: 1790
Study 25212749 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron (0.5mg/day)
Number of subjects: 77
Study 25212749 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline (200mg/day)
Number of subjects: 77
Study 25212749 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 77
Study 25212749 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron (0.5mg/day) with DRD4 >7 repeats
Number of subjects: 77
Study 25212749 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline (200mg/day) with DRD4 <7 repeats
Number of subjects: 77
Study 23094559 — intervention group
Group type: EXPERIMENTAL
Intervention: Twin-block
Number of subjects: 75
Study 23094559 — intervention group
Group type: EXPERIMENTAL
Intervention: Forsus (FRD)
Number of subjects: 75
Study 23094559 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 75
Study 19575791 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief lifestyle counselling delivered by an Alcohol Health Worker (AHW)
Number of subjects: 9
Study 19575791 — intervention group
Group type: EXPERIMENTAL
Intervention: Short screening instruments (M-SASQ, FAST, SIPS-PAT)
Number of subjects: 9
Study 19575791 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening and brief interventions
Number of subjects: 9
Study 19575791 — intervention group
Group type: EXPERIMENTAL
Intervention: Performance using a gold-standard screening test (AUDIT)
Number of subjects: 9
Study 19575791 — intervention group
Group type: EXPERIMENTAL
Intervention: Quantity and frequency of alcohol consumed
Number of subjects: 9
Study 19575791 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol-related problems
Number of subjects: 9
Study 19575791 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivation to change
Number of subjects: 9
Study 19575791 — intervention group
Group type: EXPERIMENTAL
Intervention: Health related quality of life
Number of subjects: 9
Study 19575791 — intervention group
Group type: EXPERIMENTAL
Intervention: Service utilisation
Number of subjects: 9
Study 17265490 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucosamine sulfate 1,500 mg once daily (n = 106)
Number of subjects: 318
Study 17265490 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetaminophen 3 gm/day (n = 108)
Number of subjects: 318
Study 17265490 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 104)
Number of subjects: 318
Study 17265490 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucosamine sulfate
Number of subjects: 318
Study 17265490 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetaminophen
Number of subjects: 318
Study 17265490 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 318
Study 15354322 — intervention group
Group type: EXPERIMENTAL
Intervention: Conjugated linoleic acid (CLA) 6 g/day
Number of subjects: 0
Study 15354322 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 15354322 — intervention group
Group type: EXPERIMENTAL
Intervention: Conjugated linoleic acid (CLA)
Number of subjects: 0
Study 11823887 — intervention group
Group type: EXPERIMENTAL
Intervention: 192 mg naltrexone base
Number of subjects: 12
Study 11823887 — intervention group
Group type: EXPERIMENTAL
Intervention: 384 mg naltrexone base
Number of subjects: 12
Study 11823887 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 9821032 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardised B-mode ultrasonic images of carotid plaques
Number of subjects: 119